在急性心力衰竭中使用雾化支气管扩展剂:对结果的影响
Òscar Miró1,2, Nicole Ivars3,4, Begoña Espinosa4
1Emergency Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Catalonia, Spain. omiro@clinic.cat.
Internal and emergency medicine
|October 30, 2025
概括
在没有明确迹象的急性心力衰竭 (AHF) 患者中,急诊室使用支气管扩展剂是常见的,并且与更糟糕的结果有关. 临床医生应避免在AHF中开处方支气管扩展剂,除非临床上有理由.
科学领域:
- 心脏病学 心脏病学
- 紧急医疗 紧急医疗
- 肺部病理学 肺部病理学
背景情况:
- 在没有明确指示的情况下,在急性心力衰竭 (AHF) 患者中使用支气管扩展剂是一个临床问题.
- 了解与这种未经支持的使用相关的因素及其对结果的影响至关重要.
研究的目的:
- 为了确定与急诊部 (ED) AHF患者未得到支持的支气管扩展剂使用相关的患者和情节相关因素.
- 为了确定这种使用是否会影响短期结果.
主要方法:
- 对EAHFE注册表 (2014-2022) 的二次分析,涉及10,514名AHF患者.
- 排除患有慢性肺病或接受慢性支气管扩展剂治疗的患者.
- 分析了支气管扩展剂使用与41个因素之间的关联,以及对住院,住院死亡率,长时间住院和30天死亡率的影响.
主要成果:
- 21%的AHF患者在没有明确指示的情况下接受支气管扩展剂.
- 没有支持的支气管扩展剂使用与感染,低脉冲氧计,呼吸困难,功能障碍,低心力输出迹象和低血症有关.
- 支气管扩展剂的使用与住院治疗 (OR 1.403),住院死亡 (OR 1.279) 和30天死亡率 (HR 1.215) 的增加有关.
结论:
- 在缺乏指示的AHF患者中,雾化支气管扩展剂治疗是常见的,并且与不良的短期结果相关.
- 这项研究不能最终证实因果关系,但表明了强烈的关联.
- 建议急诊医生在没有明确迹象的情况下停止对AHF患者的支气管扩展剂处方.
相关概念视频
Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
COPD: Management Using Bronchodilators and Corticosteroids
719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K


